Menu
Recruiting NCT06723639

Restoring Anatomy of Ruptured Achilles Tendon

No phase Interventional Achilles Tendon Rupture

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: A new two-layer surgical technique, Standard non-surgical treatment.
Who it may be relevant to
Registry conditions: Achilles Tendon Rupture. Basic parameters: 18 years — 67 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Denmark, Sweden
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effects of Restoring Achilles Tendon Anatomy After a Rupture: A Randomized Controlled Trial

Overview

The goal of this clinical trial is to investigate a new surgical approach to restore the anatomy of a ruptured Achilles tendon. We will use a new two-layer technique followed by rehabilitation and find out how it influence the patients clinical outcome, muscle and tendon structure, and function after one year and compare with a standard non-surgical approach followed by rehabilitation. Participants will be randomized to 1) NEWSUR: A new two-layer surgical technique followed by rehabilitation regime or 2) CONSER: A standard non-surgical treatment followed by rehabilitation . We hypothesize that restoring the anatomy of the ruptured mid-substance Achilles tendon using a new two-layer surgery technique followed by rehabilitation will yield a more favorable patient reported outcome (ATRS) one year after rupture compared to standard non-surgical treatment followed by rehabilitation.

Interventions

  • Procedure A new two-layer surgical technique
    A new double row suturing technique attempting to restore the length of the distinct soleus and gastrocnemius portions of the Achilles tendon.
  • Other Standard non-surgical treatment
    Standard non-surgical treatment

Primary outcome measures

  • The Achilles tendon Total rupture score (ATRS) [Time frame: At 1 year]
Secondary outcome measures (10)
  • Hourly sporting activity [Time frame: 1 year]
  • Patient satisfaction [Time frame: 1 year]
  • Tampa Scale of Kinesiophobia [Time frame: 26 weeks & 1 year]
  • Heel-rise test [Time frame: 26 weeks & 1 year]
  • Ultrasonography [Time frame: 1 year]
  • Magnetic resonance imaging (MRI) [Time frame: 1 year]
  • Plantarflexion muscle strength [Time frame: 1 year]
  • Vertical jump performance [Time frame: 1 year]
  • Ankle joint range of motion (ATRA) [Time frame: 26 weeks & 1 year]
  • Knee to wall test [Time frame: 26 weeks & 1 year]

Eligibility criteria

Inclusion criteria

  • Diagnosed with a complete mid-substance Achilles tendon rupture based on clinical exam, including Thompson/Matles test, by an experienced physician.
  • Presented within 14 days from injury.
  • Understands and reads Danish.
  • No contraindications for MRI.

Exclusion criteria

  • Smoking
  • Diabetes
  • Other injuries affecting their lower limb function.
  • Contralateral Achilles tendon rupture.
  • Re-rupture.
  • Anticoagulation treatment.
  • Inability to follow rehabilitation or complete follow-up tests.
  • Immunosuppressive treatment, including systemic corticosteroid treatment.
  • Pregnant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Denmark · 2 centers
  • , Copenhagen University Hospital Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark. — Copenhagen
  • Copenhagen University Hospital, Amager-Hvidovre — Copenhagen
Sweden · 1 center
  • Sahlgrenska University Hospital — Gothenburg

Identifiers

NCT: NCT06723639 · H-24041516

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗